E3 ubiquitin ligase Cbl-b has emerged as a gatekeeper that controls the activation threshold of the T cell antigen receptor and maintains the balance between tolerance and autoimmunity. Here, we report that the loss of Cbl-b facilitates T helper 2 (Th2) and Th9 cell differentiation in vitro. In a mouse model of asthma, the absence of Cbl-b results in severe airway inflammation and stronger Th2 and Th9 responses. Mechanistically, Cbl-b selectively associates with Stat6 upon IL-4 ligation and targets Stat6 for ubiquitination and degradation. These processes are heightened in the presence of T cell receptor (TCR)/ CD28 costimulation. Furthermore, we identify K108 and K398 as Stat6 ubiquitination sites. Intriguingly, introducing Stat6 deficiency into Cblb À/À mice abrogates hyper-Th2 responses but only partially attenuates Th9 responses. Therefore, our data reveal a function for Cbl-b in the regulation of Th2 and Th9 cell differentiation.
INTRODUCTION
Antigenic stimulation of T cells drives naive CD4 T helper (Th) cells into functionally distinct subsets of Th cells that are dependent upon many factors, including the affinity of T cell receptor (TCR) for antigen, the concentration of antigen during TCR triggering, and in particular the cytokine milieu (Murphy et al., 2000) . Th1 cells are characterized by the production of proinflammatory interferon g (IFN-g) to mediate cellular immunity, whereas Th2 cells produce interleukin-4 (IL-4), IL-5, and IL-13, and are responsible for regulating humoral immunity and, in pathological conditions, asthma and allergy. Recently, newly identified Th17 cells, distinct from Th1 and Th2 cells, were shown to produce IL-17, IL-17F, IL-22, and IL-21, and mediate tissue inflammation (Harrington et al., 2006; Park et al., 2005) . In addition to Th1, Th2, and Th17, a recently identified Th subset specialized for the production of IL-9, termed Th9, was shown to be generated in the presence of transforming growth factor b (TGF-b) and IL-4 (Dardalhon et al., 2008; Veldhoen et al., 2008) . Th9 cells are related to Th2 cells in that they require signal transducer and activator of transcription 6 (Stat6), GATA-binding protein 3 (GATA3), and interferon-regulatory factor 4 (IRF4) for development but are distinct from Th2 cells in their requirement for PU.1 Kaplan, 2013; Staudt et al., 2010) . Th9 cells have also been shown to contribute to allergic inflammation Kaplan, 2013; Yao et al., 2013) .
IL-4 is the determining factor for Th2 cell differentiation. In this regard, IL-4 is a key cytokine in the development of allergic inflammation (Chatila, 2004) . Binding of IL-4 to the IL-4 receptor (IL-4R) triggers phosphorylation of Janus kinase-1 (JAK-1) and JAK-3, leading to the activation of Stat6. Tyrosine-phosphorylated Stat6 forms homodimers and translocates into the nucleus, where it binds IL-4-responsive elements (Takeda et al., 1996; Wurster et al., 2000) , which, together with NF-AT, AP-1, NFkB, and other TCR-induced signal mediators, activates the transcription of IL-4 as well as the transcription factor GATA3, a signature mediator of Th2 lineage commitment. Stat6 has also been documented to be critical for induction of Th9 cell differentiation (Goswami et al., 2012) . However, the molecular basis of how the signals derived from TCR and IL-4R can be integrated has yet to be defined.
Cbl-b is an E3 ubiquitin ligase that contains multiple domains, including a protein tyrosine kinase-binding (TKB) domain, a RING-finger (RF) domain, and a proline-rich region. The RF domain is the site in which Cbl family proteins recruit ubiquitin-conjugating enzymes, which add ubiquitin to targeted proteins. The TKB domain has been shown to recognize specific phosphotyrosine residues on target proteins for ubiquitin conjugation (Thien and Langdon, 2005) . These domains are required for Cbl proteins to regulate cell signaling and protein degradation. Gene targeting in mice has indicated that Cbl-b is a gatekeeper that maintains a balance between immunity and tolerance. Indeed, signaling via CD28 and CTLA-4 tightly regulates Cbl-b expression , which is critical for establishing the threshold for T cell activation and tolerance. In strong support of this notion, Cblb À/À T cells are resistant to anergy induction in vitro and in vivo (Heissmeyer et al., 2004; Jeon et al., 2004) . However, whether Cbl-b also plays a role in Th cell differentiation remains to be elucidated. In this study, we report that loss of Cbl-b leads to a skewed Th2 and Th9 phenotype, which results in augmented airway inflammation. Upon IL-4 stimulation, Cbl-b specifically associates with Stat6, targeting it for ubiquitination and degradation, a process that is further heightened by TCR signaling. Surprisingly, Stat6 deficiency abrogates hyper-Th2 responses but only partially attenuates Th9 responses in Cblb À/À mice. This suggests that Cbl-b regulates Th2 cell differentiation via a Stat6-dependent mechanism but regulates Th9 cell differentiation via both Stat6-dependent and -independent mechanisms.
RESULTS

Cbl-b Negatively Regulates Th2 and Th9 Cell Differentiation In Vitro
To assess whether Cbl-b affects Th cell differentiation, we measured the expression of Cbl-b protein in differentiated Th1, Th2, and Th17 cells by intracellular staining. Although the expression of Cbl-b was increased in Th1, Th2, and Th17 cells, as determined by the mean fluorescence intensity (MFI) of Cbl-b, its expression was significantly lower in Th2 cells than in Th1 and Th17 cells, suggesting that Cbl-b may play a role in Th2 cell differentiation ( Figure S1A ). The increase in Cbl-b protein expression upon chronic TCR stimulation is consistent with our previous report . To confirm this further, we assessed the expression of Cbl-b in differentiating Th1, Th2, Th9, and Th17 cells by intracellular staining. Cbl-b expression was markedly lower in Th9 and Th2 cells than in Th1 and Th17 cells during the differentiation process, with the lowest levels occurring in Th9 cells ( Figure S1B ). (Murphy et al., 1990) . Consistent with the data shown in Figure 1B , loss of Cbl-b led to biased Th2 and Th9 cell differentiation of DO11.10 T cells ( Figure 1D ).
Cblb
À/À Mice Are Highly Susceptible to Asthma Induction and Display Heightened Th2 and Th9 Responses To determine whether Cbl-b regulates Th2 and Th9 responses in vivo, we used a mouse model of allergic asthma, which has been shown to be mediated by both Th2 and Th9 cytokines (Kaplan, 2013) . As shown in Figure 2A , after immunization and challenge with OVA, Cblb À/À mice displayed more severe inflammatory cell infiltration in the perivascular and peribronchial areas, goblet cell metaplasia, and increased mucus production, as determined by hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) staining of lung sections. As expected, Cblb À/À mice had significantly more infiltrating cells and eosinophils in bronchoalveolar lavage (BAL) fluid than WT mice ( Figure 2B ). Airway hyperresponsiveness (AHR) is a hallmark of asthma and is often associated with increased airway inflammation (Pernis and Rothman, 2002) . To investigate whether the severe airway inflammation in Cblb À/À mice also leads to heightened AHR, we measured respiratory system resistance (Rsr) changes in response to methacholine (MetCh) aerosol at 24 hr after the final dose of OVA challenge as described previously . We found that Cblb À/À mice remained hyperresponsive to MetCh ( Figure 2C ). Cytokine analysis showed that Cbl-b À/À mice had significantly higher levels of IL-4, IL-5, IL-13, and IL-9 in BAL fluid compared with WT mice, which closely correlated with serum immunoglobulin E (IgE) production (Figure 2D) . Note that the IFN-g level in the BAL of Cblb À/À mice was comparable to that of WT mice ( Figure 2D ). These data indicate that the loss of Cbl-b specifically inhibits Th2 and Th9 responses in vivo.
As Cbl-b deficiency has been shown to affect B cells, monocytes, and mast cells (Bachmaier et al., 2007; Gustin et al., 2006) , which may potentially affect Th2 cell differentiation, we investigated whether T cell-intrinsic loss of Cbl-b results in heightened airway inflammation and aberrant Th2 responses. We therefore analyzed BALB/c nude mice that were reconstituted with WT or Cblb À/À naive CD4 + CD25 À T cells. As shown in Figure 2E , BALB/c nude mice that received naive Cblb À/À CD4 + T cells displayed more severe airway inflammation as well as heightened IL-4, IL-5, IL-9, and IL-13 in the BAL fluid, and IgE in the serum, than those that received naive WT CD4 + T cells ( Figure 2F ). These findings indicate that Cbl-b deficiency in T cells is sufficient for stronger Th2 and Th9 responses in vivo.
As loss of Cbl-b lowers the threshold for T cell activation (Bachmaier et al., 2000; Guo et al., 2012) , one would expect that the heightened Th2 and Th9 responses 2D and 2F) , because the lower threshold should also lead to enhanced IFN-g in the BAL fluid.
Cbl-b Selectively Inhibits IL-4/Stat6 Signaling in T Cells
We next sought to determine the molecular mechanism by which Cbl-b inhibits Th2 and Th9 cell differentiation. It has been well documented that signals derived from both the TCR and IL-4R are required for Th2 or Th9 cell differentiation (Wan and Flavell, 2009; Kaplan, 2013) . It has been shown that Cbl-b does not regulate TGF-b signaling in T cells (Harada et al., 2010; Qiao et al., 2013) . We previously showed that TCR/CD28-induced activation of MAPKs, NF-kB, and NF-AT is comparable between WT and Cblb À/À T cells (Qiao et al., 2008) , suggesting that the potentiation of Th2 and Th9 cell differentiation in the absence of Cbl-b may be due to augmented expression of IL-4R or aberrant activation of IL-4R signaling. The expression of IL-4Ra was comparable between WT and Cblb À/À CD4 + T cells (data not shown),
suggesting that the heightened Th2 and Th9 cell differentiation in Cblb À/À T cells does not result from increased IL-4Ra expression.
Triggering of IL-4R by IL-4 induces activation of JAKs/Stat6 signaling and is essential for initiation of both Th2 and Th9 cell differentiation (Kaplan et al., 1996; Kaplan, 2013 Figure 3B ). The kinetics of Stat6 phosphorylation revealed a first peak at 0.5 hr after stimulation, a second peak at day 2, a decline at day 3, and another increase at days 4 and 5. Our data suggest that the first peak of Stat6 phosphorylation at Y641 may represent the direct effect of exogenous IL-4 added in the culture, whereas the second and third peaks may be due to the endogenous secretion of IL-4 in the culture. Since Stat6 is important for the induction of GATA3 (Murphy et al., 2000) , we measured the nuclear expression of Stat6, GATA3, and other transcription factors involved in Th2 cell differentiation, and IRF4 from differentiated Th9 cells. We found that expression of Stat6, GATA3, and IRF4 was increased in Cblb À/À
CD4
+ T cells ( Figure 3C ). In contrast, the nuclear expression of T-bet, the master transcription factor for Th1 cell differentiation (Szabo et al., 2000; Murphy et al., 2000) , was comparable between WT and Cblb À/À CD4 + T cells under Th1-biased conditions ( Figure 3C ), consistent with the comparable Th1 cell differentiation in vitro between WT and Cblb À/À T cells, as shown in Figure 1B . We also did not observe an increase in PU. GST-Stat6 (aa 1-680) or GST was incubated with lysates from CD4 + T cells that had been stimulated with IL-4, anti-CD3 plus anti-CD28, or both. As shown in Figure 4B , Cbl-b bound to GST-Stat6 only upon TCR/CD28 stimulation, and none of the other E3 ubiquitin ligases tested bound to Stat6. To determine whether Cbl-b also affects the differentiation of other Th subsets, we investigated whether Cbl-b could associate with other Stats. We found that Cbl-b did not bind to Stat1 upon IFN-g stimulation, to Stat4 upon IL-12 stimulation, or to Stat3 upon IL-6 stimulation ( Figure S3A ). Therefore, Cbl-b appears to specifically regulate Stat6 during Th2 and Th9 cell differentiation.
To assess whether c-Cbl regulates Th2 cell differentiation, we made use of c-Cbl À/À mice . Naive CD4 (2) phosphotyrosine residues of Cbl-b may bind to the SH2 domain of Stat6 upon TCR/CD28 stimulation. To investigate the modes of interaction, we used 293T cells that lack detectable Stat6 but retain other IL-4R signaling components necessary for Stat6 activation (Mikita et al., 1996) . To determine whether IL-4-induced Cbl-b-Stat6 interaction is mediated by Cbl-b's TKB domain, we transfected 293T cells with hemagglutinin (HA)-tagged Cbl-b or Cbl-b N1/3 (TKB only), or Cbl-b C2/3 (without TKB) mutants ( Figure 4C ) together with Flag-tagged Stat6, and stimulated them with IL-4. We found that Cbl-b and Cbl-b N1/ 3, but not Cbl-b C2/3, bound to Stat-6, suggesting that IL-4-induced Cbl-b-Stat-6 association requires the Cbl-b TKB domain ( Figure 4D ). To define whether TCR/CD28-mediated Cbl-b-Stat-6 association is mediated by the interaction of tyrosine-phosphorylated Cbl-b and the Stat6 SH2 domain, we generated GST-Stat6 SH2 recombinant proteins ( Figure 4E ) and performed a GST pull-down assay. As shown in Figure 4F , GST-Stat6 (aa 1-680) and GST-Stat6 SH2, but not GST-Stat6 TAD, bound to Cbl-b in CD4 + T cells stimulated with TCR/ CD28, supporting the notion that the Stat6 SH2 domain interacts with tyrosine residues of Cbl-b. Thus, Cbl-b's interaction with Stat6 can occur via either its TKB domain or phosphotyrosine residues.
To test whether IL-4-induced Cbl-b-Stat6 interaction interferes with TCR/CD28-induced Cbl-b-Stat6 association, we performed a competition assay using a phosphopeptide derived from IL-4R, which binds to the SH2 domain of Stat6 (Hou et al., 1994; Mikita et al., 1998) . The phosphopeptide abrogated both IL-4-and TCR/CD28-induced Cbl-b-Stat6 interaction (Figure S4) because binding of the peptide to the SH2 domain of Stat6 blocks its interaction with the IL-4R. This in turn prevents Stat6 tyrosine phosphorylation, leading to the inability of Stat6 to bind to Cbl-b's TKB domain and phosphotyrosine residues. In support of this, comparable binding levels of Cbl-b to Stat6 were observed in T cells stimulated with TCR/CD28 or TCR/ CD28/IL-4, suggesting that IL-4-induced Cbl-b-Stat6 association does not interfere with the interaction between Cbl-b and Stat6 induced by TCR/CD28 ( Figures 4A and 4B) . Furthermore, Cbl-b interacted with Stat6 in the cytosol, but not in the nuclei, as revealed by coimmunoprecipitation ( Figure 4G ).
Stat6 Phosphorylation at Y641 Is Required for Its Ubiquitination
The phosphorylation of Stat6 at Y641 is a critical step for its catalytic activity (Mikita et al., 1998) . To determine the relationship between Stat6 Y641 phosphorylation and Stat6 ubiquitination, we first examined the kinetics of Stat6 Y641 phosphorylation and ubiquitination, and Cbl-b degradation. Stat6 Y641 phosphorylation and ubiquitination both occurred at 1 min of ligation through CD3/CD28 and IL-4, but Stat6 phosphorylation peaked at 5-15 min and then declined ( Figure S5A, top) . In contrast, Stat6 ubiquitination peaked at 30-60 min after stimulation. Cblb degradation occurred at 15 min and was maintained at lower levels at 60 min of TCR/CD28/IL-4 stimulation ( Figure S5A , bottom). These data suggest that Stat6 phosphorylation at Y641 may be required for Stat6 ubiquitination and degradation. This was verified with the Stat6 Y641 mutant (Y641W), which abrogated ubiquitination induced by IL-4 ( Figure S5B ). Collectively, these data strongly indicate that phosphorylation at Y641 is required for Stat6 ubiquitination.
Cbl-b Is the E3 Ubiquitin Ligase for Stat6
To identify whether Cbl-b acts as an E3 ubiquitin ligase for Stat6, we coexpressed HA-tagged Cbl-b or Cbl-b C373A mutant, in which the active-site cysteine at position 373 is substituted with alanine Figure 5B, top) . In further support of this observation, CD4 + T cells isolated from mice expressing the Cbl-b RF C373A mutation resulted in abrogation of Stat6 ubiquitination ( Figure 5B , bottom). Further analysis showed that IL-4-induced Stat6 degradation was exacerbated in TCR/CD28 signaling, and this was completely inhibited by Cbl-b deficiency or the proteasome inhibitor MG-132 ( Figure 5C ). The key role of IL-4R signaling was further demonstrated by the observation that TCR/CD28 stimulation alone did not induce Stat6 degradation ( Figure 5D ). To determine whether Cbl-b ubiquitin ligase activity is critical for Th2 development, we performed a Th2 cell differentiation assay (legend continued on next page) using CD4 + T cells from the Cbl-b C373A mutant mice. As expected, the Cbl-b C373A mutation resulted in heightened Th2 cell development in vitro ( Figure 5E ). Collectively, our data establish Cbl-b as a key E3 ubiquitin ligase for regulating Stat6.
Lysines 108 and 398 Are the Ubiquitination Sites of Stat6
To determine the lysine residue(s) responsible for Stat6 ubiquitination, we first used the Bayesian Discriminant Method (BDM-PUB; http://bdmpub.biocuckoo.org/) to predict potential ubiquitination sites. We identified 22 potential lysine residues within Stat6, and chose the 14 residues with scores higher than 1.0 (K108, K194, K199, K252, K307, K361, K367, K369, K374, K374, K398, K618, K621, and K647; Figure S6A ). To determine the Stat6 ubiquitination site(s), we made point mutations (K to R) at each lysine. Only mutations at K108 and K398 significantly diminished Stat6 ubiquitination in 293T cells induced by IL-4 stimulation ( Figures 6A and S6B Figure 7C ), and inhibited total serum IgE titers, eosinophil infiltration, and Th2 cytokines (IL-4, IL-5, and IL-13) in the BAL of Cblb À/À mice ( Figure 7D ). In contrast, Stat6 deficiency only moderately attenuated IL-9 levels in the BAL of Cblb À/À mice ( Figure 7D ). These data are consistent with the fact that airway inflammation was completely diminished in Stat6 À/À mice, whereas some residual airway inflammation was observed in Cblb À/À Stat6 À/À mice ( Figure 7C ). To further confirm whether the residual airway inflammation in Cblb À/À Stat6 À/À mice was due to Th9 responses, we treated Cblb À/À Stat6 À/À mice with a neutralizing anti-iL-9 antibody. As expected, anti-iL-9 treatment completely abrogated residual airway inflammation in Cblb Figure 7C ).
Stat6 has been shown to be required in airway epithelial and smooth muscle cells in addition to Th2 and Th9 cells (Matsukura et al., 2001; Perkins et al., 2011 Figure S7 ). Taken together, our data demonstrate that Stat6 is the target for Cbl-b during Th2 cell differentiation both in vitro and in vivo. Our data also suggest that Th9 cell differentiation regulated by Cbl-b is mediated by both Stat6-dependent and -independent mechanisms.
DISCUSSION
Cblb À/À mice are highly susceptible to autoimmunity Jeon et al., 2004) , which is believed to be mediated by Th17 (Bettelli et al., 2007; Korn et al., 2009 ). Therefore, it is possible that Cbl-b may also regulate Th17 cell differentiation. However, our in vitro studies suggest that loss of Cbl-b does not affect Th17 cell differentiation, which contradicts a recent report in which IL-17 production, but not IL-17 intracellular staining, was used as a readout for Th17 cells (Gruber et al., 2009) . It is possible that Cbl-b deficiency in other cell types, such as B cells and monocytes/macrophages, may affect in vivo Th17 responses. Indeed, Cbl-b deficiency results in hyperactivation of B cells via BCR (Sohn et al., 2003) or CD40 , and monocytes via TLR-4 (Bachmaier et al., 2007) . The heightened production of proinflammatory cytokines via B cells and/or monocytes/macrophages in the absence of Cbl-b may eventually affect Th17 responses in vivo. In keeping with this scenario, we have found that Cblb À/À mice are highly susceptible to experimental autoimmune myocarditis (EAM), but it seems Figures 1B-1D ). Therefore, our data collectively indicate that Cbl-b specifically inhibits Th2 and Th9 cell differentiation, providing a potential pharmaceutical target for allergic asthma. Our data differ from that reported by Oh et al. (2011) , who failed to observe heightened airway inflammation and Th2 and Th9 responses in Cblb À/À mice upon OVA/alum immunization protocol. The increased airway inflammation they observed in Cblb À/À mice upon intranasal challenge was predominantly mediated by a Th1 response in the lung. This discrepancy may be due to the different genetic backgrounds of the mice (B6 versus BALB/c) and/or the doses of OVA used. Recent studies indicate that Stat6 appears to be required for Th9 cell differentiation (Goswami et al., 2012; Kaplan, 2013) . Surprisingly, although we observed a significant increase in Th9 cell responses in vitro and in vivo in the absence of Cbl-b (Figures 1 and 2 ), Stat6 deficiency only partially reduced this Th9 response in vitro and in vivo (Figures 7 and S7 ). This is supported by evidence that some residual airway inflammation was still present in Cblb
Stat6
À/À mice (Figures 7 and S7) . Therefore, Cbl-b, through targeting Stat6 for ubiquitination, inhibits Th2 responses, but Cbl-b inhibits Th9 responses via both Stat6-dependent and -independent mechanisms. We found that Stat6 specifically binds Cbl-b upon IL-4 stimulation, and that TCR/CD28 stimulation strengthens this interaction. It seems that Cbl-b interacts with Stat6 via two different mechanisms depending upon the stimuli. IL-4-induced Cbl-bStat6 association requires the Cbl-b TKB domain, which potentially interacts with tyrosine residues of Stat6, whereas (legend on next page) TCR/CD28-induced Cbl-b-Stat6 interaction may be mediated by phosphorylated Cbl-b C-terminal tyrosine residues and the SH2 domain of Stat6. In keeping with these observations, we found that Stat6 undergoes proteasomal modification upon IL-4 treatment, which is heightened by TCR/CD28 stimulation, whereas this process is abrogated in the absence of Cbl-b ( Figure 5C ). Although it is unknown why TCR/CD28 stimulation does not induce Stat6 ubiquitination but induces a strong interaction between Cbl-b and Stat6, it is possible that the orientation of this interaction is unable to promote the transfer of ubiquitin, whereas the binding of the Cbl-b TKB domain to phosphotyrosine residues of Stat6 upon IL-4 stimulation provides a correctly aligned interaction that can allow Stat6 ubiquitination. Our data demonstrate that Stat6 is ubiquitinated at K108 and K398 by Cbl-b, and that Stat6 ubiquitination is a critical posttranslational regulatory mechanism for Stat6. Although it was previously reported that Stat6 may be modified by calciumdependent proteases via a proteolytic mechanism (Zamorano et al., 2005) , it remained unknown whether Stat6 is regulated via the ubiquitin-proteasome pathway during Th2 and Th9 cell differentiation. Our study demonstrates that Stat6 is regulated by the ubiquitination-proteasome pathway, and to identify Cbl-b as the E3 ubiquitin ligase that targets Stat6. Therefore, we have identified a mechanism for Cbl-b in regulating Th2 and Th9 cell differentiation that may serve as an important therapeutic target for allergic diseases, including asthma.
EXPERIMENTAL PROCEDURES Mice
Details regarding the mice used in this study are provided in the Supplemental Experimental Procedures. All experimental protocols followed NIH guidelines and were approved by the institutional animal care and use committees of the University of Chicago and Ohio State University. All of the mice were 6-10 weeks old when they were used for experiments.
In Vitro Th1, Th2, Th9, and Th17 Differentiation Assays Naive CD4 + T cells isolated from WT and Cblb À/À mice were stimulated with plate-bound anti-CD3 (2 mg/ml) and anti-CD28 (1 mg/ml) in the presence of Th1, Th2, Th17, or Th9 cytokine cocktails as previously described . Details are provided in the Supplemental Experimental Procedures.
Immunoprecipitation and Western Blotting
The conditions for immunoprecipitation and immunoblotting were described previously Qiao et al., 2008) . Details are provided in the Supplemental Experimental Procedures.
Asthma Induction
Mice (five mice/group) were immunized by intraperitoneal (i.p.) injection of OVA (100 mg/ml; Sigma-Aldrich) adsorbed to 2 mg of an aqueous solution of aluminum hydroxide and magnesium hydroxide (Alum; Fischer Scientific) on day 0 and day 14. After 21 days, challenge doses of OVA were given through the airways. Details are provided in the Supplemental Experimental Procedures.
Statistical Analysis
A two-tailed Student's t test was applied for statistical comparison of two groups or, when appropriate, two-way ANOVA followed by Bonferroni's post hoc test for multiple comparisons and a Mann-Whitney test for nonparametric data (asthma scoring). A p value of 0.05 or less was considered significant. , and Cblb
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Mice
WT BALB/c, Stat6 -/-, and DO11.10 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Cblb -/-mice were described previously (Bachmaier et al., 2000) , and activated with anti-CD3 and anti-CD28 in the presence 10 µg/ml anti-IL-4.
Twenty-four hours after activation, the cells were infected with retroviruses expressing GATA3-GFP or control empty vector (containing only IRES-GFP).
Three days after infection, the cells were restimulated with PMA and ionomycin in the presence of Golgi-stop for 5 hr, after which IL-4-producing cells were analyzed with intracellular staining on a GFP + gate.
The pRV3-GFP-Stat6, pRV3-GFP-Stat6 K108R, pRV3-GFP-Stat6 K398R, and pRV3-GFP-Stat6 K108/398R constructs were generated by Mutagenex
Laboratories. Naïve CD4 + CD25 − CD62L hi CD44 lo T cells from Stat6 -/-mice were activated with anti-CD3 and anti-CD28 in the presence of 10 ng/ml IL-4 (Peprotech), 10 µg/ml anti-IL-12, and 10 µg/ml anti-IFN-γ, and infected with the above lentiviral vectors, or a control vector pRV-GFP. At day 2, GFP + cells were sorted, and cultured under Th2 condition. At day 7, the cells were restimulated with PMA and ionomycin in the presence of Golgi-stop for 5 hr, and IL-4-producing cells were determined by intracellular staining on a GFP + gate. CD3 and anti-CD28 as previously described Zhang et al., 2003) . The cells were lysed in 0.5 % NP-40 lysis buffer or in RIPA buffer where indicated.
T cell isolation and activation
CD4
In vitro assay for cytokine production
Naïve CD4 + T cells were stimulated with with plate-bound anti-CD3 (2 µg/ml) plus anti CD28 (1 µg/ml) for 48 h, and the supernatants were collected for detection of IL-4, IL-5, IL-9, IL-13, IL17, and IFN-γ by ELISA with ELISA kits (eBiosciences)
In vitro Th1, Th2, Th9, and Th17 differentiation assays Naïve CD4 + T cells isolated from WT and Cbl-b -/-mice were stimulated with plate-bound anti-CD3 (2 µg/ml) and anti-CD28 (1 µg/ml) in the presence of Th1, Th2, or Th9 cytokine cocktails: IL-12 (5 ng/ml) and anti-IL-4 (10 µg/ml) (for Th1 condition), IL-4 (5 ng/ml), anti-IFN-γ (10 µg/ml), and anti-IL-12 (10 µg/ml) (for Th2 condition), and IL-4 (5 ng/ml), TGF-β (2 ng/ml), and anti-IFN-γ (10 µg/ml) for Th9 condition) for 3 days. Naïve DO11. IL-17-producing cells were determined by intracellular staining.
Asthma Induction
Mice (5 mice/group) were immunized by intraperitoneal (i.p.) injection of OVA on day 0 and day 14. After 21 days, challenge doses of OVA were given through the airways by subjecting mice to 50 ml of a solution of 20 mg/ml OVA induced into aerosol form in a Plexiglas chamber with a nebulizer for 45 min. The challenge was performed once a day for three consecutive days, and methacholine challenge was performed 24 h after the final dose of OVA. Respiratory resistance was measured through a computer-controlled small-animal ventilator (SAV) (Flexivent; SCIREQ). The mice were sacrificed and assessed for allergic inflammation of the lungs 24 hr after the last aerosol exposure. BAL fluid was collected at the sacrifice, and cytokine concentrations in the BAL fluid were measured by ELISA. Cell differentials in the BAL fluid were assessed as described 6 /mouse) which were permitted to equilibrate 30 days after transfer to avoid the effects of homeostatic proliferation . The resulting mice were immunized and challenged with OVA. The cytokine concentrations were measured in BAL fluid. Serum IgE was detected by ELISA. Where specified, mice were intravenously injected with 20 µg control antibody or anti-IL-9 (222622; R&D Systems) 30 min before each challenge .
In vivo T cell activation upon OVA/alum immunization
To measure in vivo T cell activation upon OVA/alum immunization, WT BLALB/c mice were adoptively transferred with naïve CD4 + T cells from DO11.10.Rag1 
GST pull-down assay
For the GST-Stat6 pull-down assay, 5 ug GST-Stat6, GST-Stat6 TAD, and GSTStat6 SH2 fusion protein were incubated with 200 µg of BALB/c CD4 + T cell lysates followed by glutathione-sepharose beads. The binding reactions were incubated at room temperature for 2 h. After extensive washing, the bead-bound fractions were probed with the antibodies against Cbl-b, or c-Cbl, Itch, TRAF-2, TRAF-6, and Nedd4 where indicated.
Chromatin immunoprecipitation
CD4
+ T cells from WT and Cblb -/-mice were stimulated with anti-CD3, anti-CD28, and IL-4, or anti-CD3, anti-CD28, IL-4, and TGF-β for 30 min and 24 h. The stimulated cells were cross-linked with paraformaldehyde and then sonicated.
The lysates were subjected to a ChIP assay with anti-Stat6 mAb or control IgG using ChIP assay kits (Millipore) as previously described .
Quantitative representations of the results are shown as relative band intensities measured by The Li-Cor Odyssey® Infrared Imaging System (Li-Cor). The specific primers used for the gata3 locus S7 region: forward, 5'-GCCTCTCTACTGGGCGTCTTCCAG-3', and reverse, 5'-TAGCGAGACCTAGGCTCACTGGTC-3' . The specific primers used for the Il9 promoter, forward, 5'-ACTGATACCCAGTGCCCAC, and reverse, 5'-ACACAGACCTGGGCTTTCA .
